MONTREAL and LAUSANNE,
Switzerland, Jan. 8, 2020 /PRNewswire/ -- Knight Therapeutics
Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company and
Debiopharm, a Swiss-based, global biopharmaceutical company, today
announced that they have entered into an exclusive
agreement that grants Knight the rights to commercialize
Trelstar® (triptorelin) in Canada.
Knight expects to take over commercial activities from Debiopharm's
current partner Allergan and begin recording revenues in early
2020. Previously, Trelstar® was successfully launched and
commercialized in Canada by
Paladin Labs Inc. between 2006 to 2014.
"I am excited to partner again with Debiopharm for Trelstar®,"
said Jonathan Ross Goodman, Chief
Executive Officer of Knight. "Given our team's successful history
in launching and building Trelstar® in Canada and our focus on expanding Knight's
oncology portfolio, we are well positioned to re-launch
Trelstar®."
"Given the Knight team's previous great success with Trelstar®,
we believe Knight is the right Canadian partner," said Thierry
Mauvernay, President and Delegate of the Board,
Debiopharm. "We're excited for Knight to take on the
commercialization, reenergizing Trelstar®. The product became a
treatment of reference in prostate cancer in Canada under the leadership of the current
Knight team when they were at Paladin. The product is among the
leading prostate cancer treatment options, with a proven efficacy
and safety profile."
About Trelstar® (triptorelin)
Trelstar® (triptorelin) is an agonist analogue of the natural
gonadotropin-releasing hormone (GnRH). Debiopharm has developed
three sustained-release formulations (1, 3 and 6 months) of
triptorelin pamoate. First registered in France in 1986, triptorelin is currently
marketed in more than 80 countries and is market leader in many
territories worldwide. In Canada,
triptorelin is registered for Prostate Cancer as Trelstar® and was
first approved in 1999 for the palliative treatment of hormone
dependent advanced carcinoma of the prostate gland and the
management and relief of chronic pain associated with
endometriosis.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing and
commercializing innovative pharmaceutical products for the Canadian
and select international markets. Knight Therapeutics Inc.'s shares
trade on TSX under the symbol GUD. For more information about
Knight Therapeutics Inc., please visit the company's web site at
www.gud-knight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking statements for Knight
Therapeutics Inc. and its subsidiaries. These forward-looking
statements, by their nature, necessarily involve risks and
uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. Knight
Therapeutics Inc. considers the assumptions on which these
forward-looking statements are based to be reasonable at the time
they were prepared, but cautions the reader that these assumptions
regarding future events, many of which are beyond the control of
Knight Therapeutics Inc. and its subsidiaries, may ultimately prove
to be incorrect. Factors and risks, which could cause actual
results to differ materially from current expectations are
discussed in Knight Therapeutics Inc.'s Annual Report and in Knight
Therapeutics Inc.'s Annual Information Form for the year ended
December 31, 2018. Knight
Therapeutics Inc. disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information or future events, except as required by law.
About Debiopharm
Debiopharm aims to develop innovative therapies that target high
unmet medical needs in oncology and bacterial infections. Bridging
the gap between disruptive discovery products and real-world
patient reach, they identify high-potential compounds for
in-licensing, clinically demonstrate their safety and efficacy and
then select large pharmaceutical commercialization partners to
maximize patient access globally.
Visit us www.debiopharm.com.
Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews.
CONTACT INFORMATION:
Knight Therapeutics Inc.
Samira Sakhia
President and Chief Financial Officer
T: +1-514-678-8930
F: +1-514-481-4116
info@gudknight.com
www.gudknight.com
Debiopharm
Dawn Haughton - Communication
Manager
dawn.haughton@debiopharm.com
Tel: +41-(0)21-321-01-11